GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (XBRU:NYXH) » Definitions » EV-to-EBITDA

Nyxoah (XBRU:NYXH) EV-to-EBITDA : -5.64 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nyxoah EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nyxoah's enterprise value is €236.05 Mil. Nyxoah's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-41.83 Mil. Therefore, Nyxoah's EV-to-EBITDA for today is -5.64.

The historical rank and industry rank for Nyxoah's EV-to-EBITDA or its related term are showing as below:

XBRU:NYXH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -55.8   Med: -5.76   Max: -1.14
Current: -5.64

During the past 7 years, the highest EV-to-EBITDA of Nyxoah was -1.14. The lowest was -55.80. And the median was -5.76.

XBRU:NYXH's EV-to-EBITDA is ranked worse than
100% of 489 companies
in the Medical Devices & Instruments industry
Industry Median: 15.23 vs XBRU:NYXH: -5.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Nyxoah's stock price is €9.80. Nyxoah's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.552. Therefore, Nyxoah's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Nyxoah EV-to-EBITDA Historical Data

The historical data trend for Nyxoah's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah EV-to-EBITDA Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -23.68 -15.74 -1.79 -1.83

Nyxoah Quarterly Data
Dec17 Dec18 Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.79 -3.39 -3.24 -3.22 -1.83

Competitive Comparison of Nyxoah's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Nyxoah's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nyxoah's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nyxoah's EV-to-EBITDA falls into.



Nyxoah EV-to-EBITDA Calculation

Nyxoah's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=236.046/-41.831
=-5.64

Nyxoah's current Enterprise Value is €236.05 Mil.
Nyxoah's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-41.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyxoah  (XBRU:NYXH) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nyxoah's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.80/-1.552
=At Loss

Nyxoah's share price for today is €9.80.
Nyxoah's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.552.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Nyxoah EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nyxoah's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyxoah (XBRU:NYXH) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.